Loading clinical trials...

Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery | Clinical Trials | Clareo Health

RECRUITINGNA

Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery

NCT03302195•Laval University

View on ClinicalTrials.gov

Summary

Standard Heparin management, based on total body weight, is not well established for obese patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The purpose of this study is to assess the safety and efficacy of using lean body mass (LBM) to determine pump flow rate and/or Heparin dosage in obese patients undergoing CPB.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Obese patients (BMI ≥ 30kg/m2)
•Planned cardiac surgery
•Age ≥ 18 years

Exclusion Criteria

•Permanent pacemaker
•Known intolerance to protamine
•Known or suspected allergy to the used antifibrinolytic agent
•Refusal to receive blood products
•Planned off pump coronary artery bypass
•Planned peri-operative use of desmopressin
•Known Heparin-induced thrombocytopenia
•Known deficiency in protein C, protein S, antithrombin or homozygous factor V Leiden
•Known congenital bleeding disorders
•Current endocarditis
+20 more criteria

Locations (1)

Hopital Laval

Québec, Quebec, Canada

Key Dates

Start Date

August 21, 2015

Primary Completion Date

December 31, 2024

Completion Date

December 31, 2027

Last Updated

March 10, 2023

Enrollment

410

ESTIMATED participants

Conditions

Cardiopulmonary BypassObesity

Interventions

Heparin

DRUG

cardiopulmonary bypass pump flow rate

PROCEDURE

Contacts

Hugo Tremblay, Bachelor

CONTACT

418-656-8711 hugo.tremblay@criucpq.ulaval.ca

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

RECRUITING

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 10, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery

Inclusion Criteria

Exclusion Criteria

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss